170 related articles for article (PubMed ID: 22386374)
1. Onset time of tumor repopulation for cervical cancer: first evidence from clinical data.
Huang Z; Mayr NA; Gao M; Lo SS; Wang JZ; Jia G; Yuh WT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):478-84. PubMed ID: 22386374
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
3. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy.
Dimopoulos JC; Lang S; Kirisits C; Fidarova EF; Berger D; Georg P; Dörr W; Pötter R
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):56-63. PubMed ID: 19289267
[TBL] [Abstract][Full Text] [Related]
4. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience.
Gill BS; Kim H; Houser CJ; Kelley JL; Sukumvanich P; Edwards RP; Comerci JT; Olawaiye AB; Huang M; Courtney-Brooks M; Beriwal S
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):540-7. PubMed ID: 25680598
[TBL] [Abstract][Full Text] [Related]
5. Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Zhang M; Xu HD; Pan SD; Lin S; Yue JH; Liu JR
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):966-71. PubMed ID: 22138462
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy at 14 Gy per hour to point A: preliminary results of a prospectively designed schedule for cancer of the cervix based on the linear-quadratic model.
Leborgne F; Leborgne JH; Zubizarreta E; Fowler JF; Maisonneuve J; Ferrari D; Curochquin R
Int J Gynecol Cancer; 2001; 11(6):445-53. PubMed ID: 11906547
[TBL] [Abstract][Full Text] [Related]
7. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
[TBL] [Abstract][Full Text] [Related]
8. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
10. 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes.
Kharofa J; Morrow N; Kelly T; Rownd J; Paulson E; Rader J; Uyar D; Bradley W; Erickson B
Brachytherapy; 2014; 13(4):319-25. PubMed ID: 24837024
[TBL] [Abstract][Full Text] [Related]
11. Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients. A low-field MRI study.
Schmid MP; Mansmann B; Federico M; Dimopoulous JC; Georg P; Fidarova E; Dörr W; Pötter R
Strahlenther Onkol; 2013 Mar; 189(3):238-44. PubMed ID: 23344563
[TBL] [Abstract][Full Text] [Related]
12. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study.
Eifel PJ; Moughan J; Owen J; Katz A; Mahon I; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):351-8. PubMed ID: 10030261
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia.
Lim K; Chan P; Dinniwell R; Fyles A; Haider M; Cho YB; Jaffray D; Manchul L; Levin W; Hill RP; Milosevic M
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):126-33. PubMed ID: 17768016
[TBL] [Abstract][Full Text] [Related]
14. Rapid involution and mobility of carcinoma of the cervix.
Lee CM; Shrieve DC; Gaffney DK
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):625-30. PubMed ID: 14751536
[TBL] [Abstract][Full Text] [Related]
15. Fractionation in medium dose rate brachytherapy of cancer of the cervix.
Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):907-14. PubMed ID: 8751399
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
17. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.
Huguet F; Cojocariu OM; Levy P; Lefranc JP; Darai E; Jannet D; Ansquer Y; Lhuillier PE; Benifla JL; Seince N; Touboul E
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1508-15. PubMed ID: 18676093
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
[TBL] [Abstract][Full Text] [Related]
19. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
Yoshida K; Yamazaki H; Takenaka T; Kotsuma T; Yoshida M; Furuya S; Tanaka E; Uegaki T; Kuriyama K; Matsumoto H; Yamada S; Ban C
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):765-72. PubMed ID: 19836165
[TBL] [Abstract][Full Text] [Related]
20. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
